r Several different voltage-dependent K + (K V ) channel isoforms are expressed in arterial smooth muscle cells (myocytes).
Introduction
In small, resistance-size arteries, intravascular pressure stimulates smooth muscle cell (myocyte) membrane depolarization, which activates voltage-dependent calcium (Ca V 1.2) channels, leading to an increase in [Ca 2+ ] i and vasoconstriction (Knot & Nelson, 1998; Davis & Hill, 1999) . Arterial myocyte voltage-dependent potassium (K V ) channels are also activated by membrane depolarization, stimulating a negative feedback mechanism that opposes pressure-induced depolarization and vasoconstriction (Nelson & Quayle, 1995; Yuan, 1995; Albarwani et al. 2003; Plane et al. 2005; Amberg & Santana, 2006) . This mechanism sets an equilibrium of arterial contractility that can be further modulated by vasoconstrictors and vasodilators to regulate regional organ blood flow and systemic blood pressure.
The K V channels are a family of ß40 proteins divided into 12 subclasses (K V 1-K V 12; Gutman et al. 2005) . Several K V family members are expressed in myocytes, including K V 1.2, K V 1.5, K V 2.1, K V 2.2, K V 7.1 and K V 7.4 (Xu et al. 1999; Albarwani et al. 2003; Fountain et al. 2004; Yeung et al. 2007) . The whole-cell current amplitude (I) generated by a population of K V channels is equally dependent on single-channel current (i), open probability (P O ) and the number of channels at the cell surface (N) such that I = NP O i. P O is directly controlled by membrane potential, which modifies the conformation of the voltage-sensing, arginine-rich S4 segment in K V channel subunits (Nelson & Quayle, 1995; Jiang et al. 2003) . Membrane potential also regulates the number (N) of plasma membrane-resident K V 1.5 channels in arterial myocytes (Kidd et al. 2015) . These mechanisms control functional K V channel activity (NP O ) in arterial myocytes (Nelson & Quayle, 1995; Kidd et al. 2015) . Whether vasoregulatory stimuli other than membrane potential, including vasoconstrictors, also modulate arterial contractility by controlling the surface abundance of K V channels is unclear.
Angiotensin II (Ang II) is a vasoconstrictor produced by the renin-angiotensin system (Chappell, 2016) . Angiotensin II binds angiotensin II type 1 (AT 1 ) receptors in arterial myocytes, stimulating G q/11 , leading to phospholipase C activation (Berk & Corson, 1997; Higuchi et al. 2007; Wynne et al. 2009 ). Phospholipase C cleaves phosphoinositide 4,5-bisphosphate into inositol triphosphate and diacylglycerol (DAG; Higuchi et al. 2007; Wynne et al. 2009 ). Diacylglycerol stimulates protein kinase C (PKC), which modulates a wide variety of ion channels in arterial myocytes, including Ca V 1.2, ATP-sensitive K + and Ca 2+ -activated K + channels (Hughes, 1995; Nelson & Quayle, 1995; Taguchi et al. 2000; Higuchi et al. 2007; Wynne et al. 2009; Leo et al. 2015) . Angiotensin II also inhibits K V currents in arterial myocytes through a PKC-dependent mechanism, leading to vasoconstriction (Rainbow et al. 2009 ). Whether Ang II reduces surface K V channel protein to inhibit K V currents in arterial myocytes is unclear.
Here, we tested the hypothesis that Ang II controls surface levels of K V 1.5 and K V 2.1 channels, the predominant K V isoforms expressed in rat mesenteric artery myocytes (Kidd et al. 2015) . Data suggest that Ang II decreases total and surface K V 1.5 protein in arterial myocytes through a PKC-and lysosome-dependent mechanism, which reduces whole-cell K V 1.5 currents and K V 1.5 function in pressurized arteries. In contrast, K V 2.1 total and surface protein were unaltered by Ang II. These data suggest that Ang II controls surface K V 1.5 protein abundance to modulate arterial contractility.
Methods

Ethical approval
All animal protocols were reviewed and approved by the Animal Care and Use Committee of the University of Tennessee Health Science Center, in accordance with the standards set by the National Institutes of Health. All experiments adhere to the ethical principles of The Journal of Physiology and comply with the journal's animal ethics checklist.
Preparation of tissues and isolated cells
Adult male Sprague-Dawley rats (200-250 g body mass) were purchased from Harlan Labs (Indianapolis, IN, USA) and fed ad libitum. Rats were administered CO 2 in a specially designed housing chamber until immobile, to reduce any discomfort, before being killed by I.P. injection of sodium pentobarbitone (150 mg kg −1 ). The mesenteric vasculature was removed into ice-cold physiological saline solution (PSS) that contained 112 mM NaCl, 6 mM KCl, 24 mM NaHCO 3 , 1.8 mM CaCl 2 , 1.2 mM MgSO 4 , 1.2 mM KH 2 PO 4 and 10 mM glucose, gassed with 21% O 2 , 5% CO 2 and 74% N 2 to pH 7.4. Third-and fourth-order mesenteric arteries (ß100-200 μm in diameter) were cleaned of adventitial tissue and dissected for experiments.
Individual myocytes were dissociated from arteries in isolation solution containing 55 mM NaCl, 80 mM sodium glutamate, 5.6 mM KCl, 2 mM MgCl 2 , 10 mM Hepes and 10 mM glucose, with pH adjusted to 7.4 using NaOH. Arteries were placed in prewarmed isolation solution containing 0.7 mg ml −1 papain, 1 mg ml
dithioerythreitol and 1 mg ml −1 bovine serum albumin (BSA) for 15-20 min at 37°C. Arteries were then quickly transferred to isolation solution containing 0.66 mg ml −1 collagenase F, 0.33 mg ml −1 collagenase H, 1 mg ml
BSA and 100 mM CaCl 2 for 5-10 min at 37°C. Arteries were then washed with ice-cold isolation solution and triturated with a fire-polished glass Pasteur pipette to yield single myocytes.
Surface biotinylation
Arteries were incubated with 1 mg ml −1 each of EZ-Link Sulfo-NHS-LC-LC-Biotin and EZ-Link Maleimide-PEG2-Biotin (Thermo Scientific, Waltham, MA, USA) in ice-cold PSS for 1 h at 4°C. Unbound biotin was quenched with ice-cold 100 mM glycine in PBS, then arteries were washed with ice-cold PBS. Arteries were homogenized in ice-cold radioimmunoprecipitation assay buffer containing (mM): 50 Tris, 150 NaCl and 5 EDTA, with 0.1% SDS and 1% Triton-X. Avidin beads in spin columns were used to separate the biotinylated surface protein. Biotinylated proteins were freed from the avidin beads by boiling in SDS buffer containing 5% 2-mercaptoethanol. The whole volumes of either biotinylated or non-biotinylated protein samples from each preparation were loaded into separate lanes of the same polyacrylamide gel for electrophoresis.
Western blotting
Arteries were homogenized in radioimmunoprecipitation assay buffer with 1× SDS and 5% 2-mercaptoethanol. Arterial protein lysates were separated on 7.5% SDSpolyacrylamide gels, then transferred onto nitrocellulose membranes. Membranes were blocked with 5% milk in Tris-buffered saline with 0.1% Tween 20 (TBS-T), then incubated with mouse monoclonal primary antibodies for K V 1.5, K V 2.1 (1:1000; NeuroMab, UC Davis, CA, USA) or actin (1:10000; Millipore, Billerica, MA, USA) in blocking solution overnight at 4°C. Membranes were washed with TBS-T before being incubated with horseradish peroxidase-conjugated secondary antibodies for 2 h at room temperature, followed by a second wash with TBS-T. Protein bands were developed using SuperSignal enhanced chemiluminescence substrate (Thermo Scientific) with a Kodak In Vivo Pro Imaging System. Band intensity was analysed using ImageJ software (NIH, Bethesda, MD, USA).
Immunofluorescence
Isolated myocytes were plated on poly-L-lysine-coated coverslips and maintained for 2 h in 30 mM K + PSS alone, with Ang II or with Ang II in the presence of bisindolylmaleimide (BIM) before being fixed with formalin and incubated with Alexa 488-conjugated wheat germ agglutinin (Invitrogen, Carlsbad, CA, USA), a plasma membrane stain. Myocytes were permeabilized with 0.1% Triton-X 100 and then blocked in 5% BSA before incubation with a mouse monoclonal K V 1.5 primary antibody (1:100 in 0.5% BSA; NeuroMab, UC Davis) overnight at 4°C. Myocytes were washed and incubated with an Alexa 546-conjugated donkey polyclonal secondary antibody to mouse IgG (1:100; Life Technologies, Carlsbad, CA, USA). Coverslips were washed, then secured to microscope slides using 1:1 PBS:glycerol. Images were acquired using a laser scanning confocal microscope (LSM Pascal; Carl Zeiss, Thornwood, NY, USA). Alexa 488 and 546 were excited at 488 and 543 nm, respectively, with emission collected at 505-530 and ࣙ560 nm, respectively. Zeiss Pascal system software was used to calculate weighted pixel colocalization coefficient values. The RG2B plugin for ImageJ was used to isolate colocalization pixel data, with automatic selection intensity threshold values for the red and green channels. Colocalization data were expressed as the average of the corresponding red and green channels, producing an image displaying only colocalized pixels.
Arteries were incubated with 1 mg ml −1 each of EZ-Link Sulfo-NHS-LC-LC-Biotin and EZ-Link Maleimide-PEG2-Biotin (Thermo Scientific) in PSS for 1 h at 4°C. Unbound biotin was quenched with ice-cold 100 mM glycine in PBS, and arteries were washed with ice-cold PBS. Arteries were then postfixed with 4% paraformaldehyde in PBS overnight. After dehydration, vessels were embedded in paraffin and 5-μm-thick sections cut using a microtome and mounted on slides. Sections were deparaffinized and blocked in 5% BSA before incubation with Alexa Fluor 546 streptavidin (Molecular Probes, Eugene, OR, USA) and 4 ,6-diamidino-2-phenylindole, dihydrochloride (DAPI; Thermo Scientific) for 1 h at 37°C. Slides were then washed in PBS. Images were acquired using a laser-scanning confocal microscope and a ×63 objective (Zeiss 710; Carl Zeiss). The DAPI and Alexa 546 were excited at 405 and 561 nm, respectively, with emission collected at ࣘ437 and ࣙ552 nm, respectively.
Patch-clamp electrophysiology
Experiments were performed on isolated myocytes that were allowed to adhere to a glass coverslip for ß15 min before experimentation. Whole-cell currents were recorded using an Axopatch 200B amplifier and Clampex 10.4 (Molecular Devices, Sunnyvale, CA, USA). The K V currents were activated from a holding potential of −70 mV by applying stepwise depolarizations to between −60 and +50 mV. Bath solution contained (mM): 120 NaCl, 3 NaHCO 3 , 4.2 KCl, 1.2 KH 2 PO 4 , 0.5 MgCl 2 , 1.8 CaCl 2 , 10 glucose, 1 TEA and 10 Hepes, and pH was adjusted to 7.4 with NaOH. Pipette solution contained (mM): 110 potassium gluconate, 30 KCl, 0.5MgCl 2 , 5 Na 2 ATP, 1 GTP, 10 EGTA and 5 Hepes, and pH was adjusted to 7.2 with KOH. The K V currents were digitized at 5 kHz and filtered at 1 kHz. Offline analysis was performed using Clampfit 10.4 (Molecular Devices).
Pressurized artery myography
Third-order mesenteric artery segments (0.5-1 mm in length, 150-200 μm diameter) were denuded of J Physiol 595.5 endothelium by introducing air into the lumen for ß1 min. Arteries were then cannulated at each end in a temperature-controlled perfusion chamber (Living Systems Instrumentation, St Albans City, VT, USA) and continuously perfused with PSS. Intravascular pressure was modulated using an attached reservoir and monitored with a pressure transducer. Arterial diameter was measured using a closed-circuit camera and IonWizard edge-detection software (IonOptix, Westwood, MA, USA). Myogenic tone was calculated as: 100 × (1 − D Active /D Passive ), where D Active is active arterial diameter and D Passive is arterial diameter in Ca 2+ -free PSS supplemented with 5 mM EGTA.
Statistical analysis
Data were analysed using ANOVA with Newman-Keuls post hoc test using GraphPad Prism 5 (GraphPad Software Inc., La Jolla, CA, USA). All data are expressed as mean values ± SEM. A value of P < 0.05 was considered significant.
Results
Angiotensin II reduces plasma membrane K V 1.5 channels via protein kinase C activation in arterial myocytes
Membrane potential controls both the surface abundance and total protein of K V 1.5 channels in arterial myocytes (Kidd et al. 2015) . Arterial isolation (2 h) in PSS containing 6 mM K + at 37°C led to a decrease in K V 1.5 total protein to ß31% of that in fresh isolated (0 h) control arteries ( Fig. 1A and B). K V 1.5 protein loss was prevented by maintenance in a PSS containing 30 mM K + , which depolarizes arterial myocytes to ß−40 mV, a membrane potential similar to arteries at physiological intravascular pressure ( Fig. 1A and B; Knot & Nelson, 1998) . In contrast, K V 2.1 total protein was unaltered by arterial isolation (2 h) in PSS containing either 6 or 30 mM K + (Fig. 1A and B) . These data are consistent with previous findings (Kidd et al. 2015) .
We have previously demonstrated that biotin labels plasma membrane proteins, but not intracellular proteins, in rat resistance-size cerebral arteries (Bannister et al. 2009 ). Arterial biotinylation has been used to measure the abundance and cellular distribution of surface and intracellular ion channels and auxiliary subunits in arterial myocytes (Adebiyi et al. 2010; Bannister et al. 2009 Bannister et al. , 2016 Crnich et al. 2010; Thomas-Gatewood et al. 2011; Narayanan et al. 2013; Evanson et al. 2014; Nourian et al. 2014; Leo et al. 2015) . To determine whether biotin permeates and labels proteins in the wall of rat mesenteric arteries, immunofluorescence was performed. Mesenteric arteries were exposed to biotin reagents, after which sections were cut and incubated with Alexa Fluor 546-labelled streptavidin. Confocal imaging demonstrated that biotin labelled proteins throughout the wall of mesenteric arteries, indicating efficient labelling consistent with data in cerebral arteries ( Fig. 1C ; Bannister et al. 2009 ).
The regulation of surface K V 1.5 and K V 2.1 protein by Ang II, a vasoconstrictor, was studied using arterial biotinylation in depolarized (30 mM K + ) arteries. Angiotensin II (applied for 2 h) reduced both total and surface K V 1.5 to ß38 and ß42% of control values, respectively (Fig. 1A, B, D and E) . In contrast, Ang II did not alter K V 1.5 cellular distribution, which was calculated as the percentage of total K V 1.5 protein present at the cell surface ( Fig. 1D and F) . Angiotensin II also did not alter total or surface K V 2.1 protein or K V 2.1 cellular distribution (Fig. 1A, B , D, E and F) . To ensure that the avidin beads used to pull down biotinylated proteins were 100% efficient, Western blots were probed with horseradish peroxidase-conjugated avidin. Horseradish peroxidase labelling was observed only in the surface lane and not in the intracellular lane, indicating that biotinylated proteins did not escape pull-down and contaminate the non-biotinylated protein fraction (Fig. 1G ). These data indicate that Ang II reduces both total and surface K V 1.5 to a similar extent, but does not alter K V 2.1 protein, in mesenteric arteries.
The binding of many vasoconstrictors, including Ang II, to their plasma membrane receptors stimulates G q/11 in arterial myocytes (Berk & Corson, 1997) . G q/11 activates phospholipase C, leading to an elevation in DAG, which stimulates PKC (Berk & Corson, 1997) . We tested the hypothesis that Ang II controls K V 1.5 protein through a PKC-mediated mechanism. Bisindolylmaleimide, a PKC-specific inhibitor, blocked the Ang II-induced decrease in both total and surface K V 1.5 protein (Fig. 1B-F) . In contrast, BIM, when applied alone, did not alter total or surface K V 1.5 protein or K V 1.5 cellular distribution (Fig. 1B-F) . Bisindolylmaleimide also did not change total or surface K V 2.1 when applied either alone or together with Ang II (Fig. 1B-F) . A membranepermeant, myristoylated PKC inhibitory peptide (Myr-RFARKGALRQKNV) also blocked the Ang II-induced reduction in both total and surface K V 1.5 protein, but did not alter K V 2.1 protein (Fig. 1B-F) . These data indicate that Ang II reduces total and surface K V 1.5 protein through a PKC-dependent mechanism in mesenteric arteries.
Immunofluorescence was performed to measure the regulation of K V 1.5 localization by Ang II in isolated mesenteric artery myocytes. Angiotensin II reduced K V 1.5 channel immunofluorescence colocalization with wheat germ agglutinin, a plasma membrane stain, from ß29 to ß9%, and this effect was prevented by BIM ( Fig. 2A and  B) . Taken together, these data suggest that Ang II-induced PKC activation reduces surface and total K V 1.5 channel protein in arterial myocytes. -psi; 100 µM) . B, mean data. n = 6 for each. * P < 0.05 vs. 0 h. C, immunofluorescence of a section cut from a biotinylated mesenteric artery labelled with Alexa Fluor 546 streptavidin (red) and DAPI (blue), a nuclear stain. Scale bars represent 20 µm. D, representative Western blot images of arterial biotinylation samples illustrating surface (S) and intracellular (I) K V 1.5 and K V 2.1 following 2 h in 30 mM K + alone (control) or in the presence of Ang II (100 nM), BIM (10 µM), Ang II plus BIM, or Ang II plus myr-psi (100 µM). E, mean data for surface protein in conditions from experiments shown in C calculated as a percentage of control surface protein. n = 6 for each. * P < 0.05 vs. control. F, quantitative analysis of the relative cellular distribution of total K V 1.5 and K V 2.1 protein in conditions from C calculated as the percentage of total protein located at the cell surface. n = 6 for each. G, representative image of a Western blot probed with horseradish peroxidase-conjugated avidin, illustrating that the avidin bead pull-down procedure is 100% efficient and that no biotinylated proteins are present in the non-biotinylated protein fraction.
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Angiotensin II stimulates K V 1.5 channel degradation in arterial myocytes K V 1.5 continuously recycles between the plasma membrane and the intracellular compartment in mesenteric artery myocytes (Kidd et al. 2015) . Conceivably, Ang II might stimulate K V 1.5 channel internalization, degradation or both in arterial myocytes. To test these possibilities, we studied regulation by bafilomycin A, a lysosomal v-ATPase and, thus, lysosomal degradation inhibitor. Bafilomycin A prevented the Ang II-mediated decrease in surface K V 1.5 protein (Fig 3A and B) . In contrast, bafilomycin alone did not alter surface K V 1.5 protein (Fig. 3A and B) . To determine whether Ang II altered channel internalization, effects on K V 1.5 cellular distribution were calculated. Angiotensin II, bafilomycin, or Ang II applied in the presence of bafilomycin did not alter the relative cellular distribution of K V 1.5 ( Fig. 3A and C) . Total and surface K V 2.1 were unaltered by Ang II, bafilomycin, or Ang II applied with bafilomycin ( Fig. 3A-C) . These data suggest that Ang II stimulates lysosomal degradation of internalized K V 1.5 protein, but indicate that Ang II does not stimulate K V 1.5 internalization in arterial myocytes.
Angiotensin II-induced PKC activation reduces K V 1.5 current density in arterial myocytes
To determine the functional effect of an Ang II-mediated reduction in surface K V 1.5 channels, patch-clamp electrophysiology was performed to measure K V 1.5 current density in isolated arterial myocytes. Arteries were exposed to 30 mM K + PSS alone (control), together with Ang II, or with both Ang II and BIM for 2 h, after which these agents were removed and myocytes isolated and used for electrophysiology. Patch-clamp solutions were designed to isolate whole-cell K V currents and reduce contamination from other current types, including large-conductance Ca 2+ -activated K + channels. Angiotensin II treatment reduced mean K V current density from ß31 to ß14 pA pF −1 , or to ß45% (at +50 mV) of that in control myocytes ( Fig. 4A and B) . Involvement of K V 1.5 channels was investigated using Psora-4, a K V 1.5 open channel blocker that inhibits currents activated during voltage pulses ( Fig. 4A ; Marzian et al. 2013) . Psora-4 reduced mean K V current density (measured at the end of voltage pulses) in control myocytes by ß18 pA pF −1 (at +50 mV; Fig. 4A  and B) . In contrast, in Ang II-treated myocytes, Psora-4 reduced mean K V current density by ß5 pA pF −1 (at +50 mV; Fig. 4A and B) . The Psora-4-induced reduction in K V current in Ang II-treated myocytes was ß28% of that in control myocytes (at +50 mV; Fig. 4A and B). Bisindolylmaleimide prevented the Ang II-induced reduction in both whole-cell K V and Psora-4-sensitive K V currents ( Fig. 4A and B) . These data illustrate that Ang II-induced PKC activation reduces surface K V 1.5 channel protein, which decreases both whole-cell and K V 1.5 current density in arterial myocytes.
Angiotensin II inhibits functional K V 1.5 channel activity in pressurized arteries
To investigate the significance of an Ang II-induced reduction in surface K V 1.5 channels in arterial myocytes, myography was performed on pressurized, endothelium-denuded myogenic third-order mesenteric arteries. Arteries were exposed to 30 mM K + PSS alone, with Ang II, or with both Ang II and BIM for 2 h. These conditions were then removed, arteries were pressurized to 80 mmHg in PSS containing 6 mM K + , and myogenic tone and acute vasoconstriction in response to Psora-4 or 4-aminopyridine (4-AP), a broad K V channel inhibitor, were measured.
In myogenic arteries that were maintained in 30 mM K + PSS (control), Psora-4 or 4-AP stimulated acute mean vasoconstrictions of ß20.6 and ß40.4 μm, respectively (Fig. 5A and B) . In contrast, Psora-4 or 4-AP contracted arteries that had been exposed to Ang II by ß8.8 and ß24.2 μm, respectively, or ß42.7 and ß59.9% of that in control arteries ( Fig. 5A and B) . Bisindolylmaleimide blocked the Ang II-induced reduction in Psora-4-and 4-AP-mediated vasoconstriction ( Fig. 5A and B) . In contrast, vasoconstriction in response to 60 mM K + was not altered by Ang II (Fig. 5C ). Myogenic tone was also similar in all three conditions: control, 16.2 ± 0.86% (n = 6); Ang II, 15.0 ± 0.83% (n = 6); and Ang II plus BIM, 15.8 ± 0.73% (n = 6). These data suggest that Ang II-induced PKC activation reduces the abundance of functional surface K V 1.5 channels in arterial myocytes.
Discussion
Angiotensin II inhibits K V currents in arterial myocytes, but the mechanisms involved are unclear. Here, we show that Ang II reduces the surface abundance of K V 1.5 channels in mesenteric artery myocytes. Angiotensin II-induced PKC activation stimulates K V 1.5 channel degradation, which reduces whole-cell K V currents in myocytes and attenuates K V function in myogenic arteries. In contrast, Ang II does not modulate surface K V 2.1 channel abundance in arterial myocytes. Thus, our data suggest that Ang II selectively decreases surface K V 1.5 protein, thereby reducing K V current density in arterial myocytes and inhibiting vasodilatation by these channels, leading to vasoconstriction. Our data here and a previous study show that membrane potential and Ang II both regulate the surface abundance of K V 1.5 channel protein in arterial myocytes (Kidd et al. 2015) . Angiotensin II binds to AT 1 receptors, which are coupled to G q/11 proteins that stimulate phospholipase C in vascular myocytes (Berk & Corson, 1997) . Phospholipase C activation elevates DAG, a PKC activator (Berk & Corson, 1997) . Protien kinase C directly phosphorylates myosin light chain kinase, which then phosphorylates myosin light chain, promoting an interaction between actin and myosin, resulting in vasoconstriction (Gallagher et al. 1997) . Data suggest that Ang II stimulates degradation of internalized K V 1.5 channels through a PKC-dependent mechanism. Bisindolylmaleimide (a selective PKC inhibitor) or a myristoylated, cell-permeant PKC inhibitory peptide prevented the Ang II-mediated reduction in surface and total K V 1.5 channels. Three isoforms of PKC are present in vascular myocytes; PKCα and PKCβ are DAG and Ca 2+ dependent, and PKCε is stimulated by DAG (Newton, 1995) . Angiotensin II-mediated PKCε activation reduces whole-cell K V currents in arterial myocytes, and PKCε inhibition reduces Ang II-induced vasoconstriction in mesenteric artery rings (Rainbow et al. 2009 ). In contrast to Ang II, membrane depolarization inhibits K V 1.5 channel degradation via Ca V 1.2 channel activation (Kidd et al. 2015) . Here, to study Ang II regulation of K V 1.5 channels in myocytes, experiments were performed in arteries depolarized with PSS containing 30 mM K + , which depolarizes myocytes to ß−40 mV, a membrane potential similar to arteries at physiological intravascular pressure (Knot & Nelson, 1998) . Although the kinases involved have not been identified, membrane potential and Ang II are likely to control K V 1.5 degradation through different mechanisms, as PKC stimulates K V 1.5 degradation and Ca V 1.2 channel activation inhibits K V 1.5 degradation. Angiotensin II-induced K V 1.5 degradation described here may be attributable to PKCε, whereas depolarization-induced K V 1.5 protection may occur as a 
currents in arterial myocytes
A, representative whole-cell K V current recordings in myocytes isolated from arteries that had been maintained for 2 h in 30 mM K + (control), 30 mM K + plus Ang II (100 nM) or 30 mM K + plus Ang II and BIM (10 µM). Currents were measured in myocytes immediately following isolation. B, mean current-voltage relationships for whole-cell (top, n = 7 for each) and Psora-4-sensitive currents (bottom, n = 7 for each). * P < 0.05 vs. control.
result of Ca 2+ -dependent PKCs or other Ca 2+ -activated kinases. Future studies should be designed to test these hypotheses.
Bafilomycin, an inhibitor of lysosomal degradation, prevented the Ang II-induced reduction in surface and total K V 1.5 protein, but did not change K V 1.5 relative cellular distribution in arterial myocytes. These data suggest that Ang II stimulates K V 1.5 channel degradation, but does not activate K V 1.5 internalization or recycling in arterial myocytes. K V 1.5 channels continuously recycle in mesenteric artery myocytes, suggesting that Ang II-induced PKC activation shuttles internalized channels into the lysosomal degradation pathway (Kidd et al. 2015) . In contrast, K V 2.1 channels do not recycle over the same time course, which may be one reason why Ang II does not stimulate degradation of these proteins. K V 1.5 channels recycle through Rab4-and Rab11-dependent pathways in HL-1 mouse atrial myocytes, H9c2 rat cardiomyoblasts and HEK293 cells expressing recombinant K V 1.5, suggesting involvement of recycling and early endosomes (McEwen et al. 2007; Zadeh et al. 2008) . Oxidative stress increased colocalization of internalized K V 1.5 channels with the chaperone heat shock protein 70, which targets proteins for ubiquitylation and degradation, in HL-1 cells (Pratt et al. 2010; Svoboda et al. 2012) . Oxyhaemoglobin stimulates K V 1.5 channel internalization through a tyrosine kinase-dependent mechanism in rabbit cerebral artery myocytes (Ishiguro et al. 2006) . Angiotensin II-induced regulation of K V 1.5 transcription is highly unlikely to explain the mechanism we describe here. Arteries were exposed to Ang II for 2 h, which is a period of time unlikely to alter K V 1.5 protein through transcription. Supporting this conclusion are our data showing that bafilomycin blocked the Ang II-mediated reduction in K V 1.5 protein. We have also previously shown that arterial depressurization for 3 h reduces K V 1.5 protein by >60% without any change in K V 1.5 mRNA, indicating that protein processing and transcription can occur independently in arterial myocytes (Kidd et al. 2015) .
Several studies have investigated trafficking pathways that modulate ion channel abundance at the cell surface in arterial myocytes. α 2 δ-1, an auxiliary subunit of voltage-dependent Ca 2+ channels, is required for trafficking of Ca V 1.2 to the cell surface in cerebral artery myocytes (Bannister et al. 2009 ). Myocyte surface expression of both Ca V 1.2 and α 2 δ-1 subunits is increased in rats with genetic hypertension, elevating Ca V 1.2 current density and producing a non-inactivating current that stimulates vasoconstriction (Bannister et al. 2012) . The surface abundance of TRPM4, a melastatin transient receptor potential channel, is 
channel activity in pressurized arteries
A, representative diameter traces for vasoconstriction stimulated by Psora-4 (100 nM) or 4-aminopyridine (4-AP, 1 mM) at an intravascular pressure of 80 mmHg for arteries maintained for 2 h in 30 mM K + alone (control) or plus Ang II (100 nM) or plus Ang II with BIM (10 µM). Initial arterial diameters before application of Psora-4 or 4-AP were normalized. B, mean data illustrating vasoconstriction stimulated by Psora-4 or 4-AP. n = 6 for each. Mean passive diameters were similar for arteries used in each data set (P > 0.05 for each, e.g. mean passive diameter for control arteries was 231.6 ± 4.7 µm, for Ang II-treated arteries 228.0 ± 4.1 µm, and for arteries treated with Ang II and BIM 232.8 ± 4.8 µm). * P < 0.05 vs. control. C, mean data for vasoconstrictive response to 60 mM K + PSS at 80 mmHg intravascular pressure. n = 6 for each.
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increased by PKCδ in cerebral artery myocytes (Crnich et al. 2010) . Nitric oxide stimulates rapid trafficking of large-conductance Ca 2+ -activated K + (BK) channel β1 subunits to the myocyte surface to activate BK channels and produce vasodilatation in cerebral arteries . Serotonin, a neurotransmitter and vasoconstrictor, reduced surface K V 1.5 channels, as determined using immunofluorescence, in pulmonary artery myocytes (Cogolludo et al. 2006) . Physiological intravascular pressure, via depolarization-induced voltage-dependent Ca 2+ channel activity, stimulates K V 1.5 channel surface expression in mesenteric artery myocytes (Kidd et al. 2015) . Here, we show that Ang II reduces surface K V 1.5, the predominant K V channel subtype, in mesenteric artery myocytes (Kidd et al. 2015) . Myocytes of other vascular beds may express different populations of K V channel subtypes (Kerr et al. 2001; Albarwani et al. 2003; Amberg & Santana, 2006; Zhong et al. 2010; Jepps et al. 2011) . As such, the regulatory pathway described here for K V 1.5 may be more relevant in some vessels than others. K V 1.5 and K V 1.2 form functional heteromultimeric channels in rat mesenteric artery myocytes and rabbit portal vein myocytes (Kerr et al. 2001; Plane et al. 2005) . Angiotensin II-mediated modulation of surface K V 1.5 may alter K V channel heteromultimer formation and abundance in arterial myocytes. Collectively, these studies indicate that multiple, distinct trafficking pathways, with differing time courses and mechanisms, modulate the surface abundance and activity of a variety of ion channels in arterial myocytes to regulate contractility.
The use of Psora-4, a K V 1.5 channel inhibitor, in patch-clamp electrophysiology and myography experiments supports our biochemical data showing that Ang II regulates K V currents and vasocontractility by modulating K V 1.5 surface expression. Psora-4 is a psoralen compound that blocks both K V 1.3 and K V 1.5 channels at low nanomolar concentrations, but is a less effective blocker of other K V 1 family members (Vennekamp et al. 2004) . There are few to no data suggesting the expression or function of K V 1.3 in contractile arterial myocytes (Cidad et al. 2010; Cheong et al. 2011) . Psoralens also weakly inhibit K V 2, K ir 2.1, BK and Ca V 1.2 channels in arterial myocytes, but at concentrations 25-150 times higher than used here (Nelson & Quayle, 1995; Vennekamp et al. 2004; Schmitz et al. 2005) . Arteries treated with Ang II developed the same amount of myogenic tone as control arteries despite the reduction in K V 1.5 function measured with Psora-4 or 4-AP. The reasons for this are unclear, but one explanation is that Ang II modulates the surface abundance of other ion channels that control arterial contractility, leading to no net effect on myogenic tone. Vasoconstriction stimulated by 60 mM K + was unaltered, indicating that Ang II does not cause non-specific alteration of contractility and does not appear to modify voltage-dependent Ca 2+ channel protein or activity. Data indicate that the Ang II-induced reduction in K V 1.5 surface protein inhibits K V currents and arterial contractility regulation by K V 1.5 channels.
In summary, we show that Ang II selectively stimulates degradation of K V 1.5 channels to reduce functional K V 1.5 channel surface abundance in mesenteric artery myocytes. Angiotensin II-mediated PKC activation stimulates lysosomal degradation of internalized K V 1.5 channels, reducing protein available for recycling. Through this mechanism, Ang II inhibits whole-cell K V 1.5 currents, thereby reducing their functional modulation of arterial contractility.
